PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1056/NEJMoa2116044
?:hasPublicationType
?:journal
  • The New England journal of medicine
is ?:pmid of
?:pmid
?:pmid
  • 34914868
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all